G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Clinical trial NCT02983071 · UNKNOWN

Trial details

NCT number: NCT02983071
Sponsor: G1 Therapeutics, Inc.
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Carcinoma, Ductal, Breast Breast Cancer Breast Neoplasm

Start date: 2017-01-01
Primary completion: 2023-06-01
Enrollment: 102

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.